A rise in disposable income and participation in equestrian sports will likely boost demand for equine pharmaceuticals
Los Angeles, California (PRWEB) December 08, 2011
In the five years to 2016, IBISWorld projects that revenue for the Equine Pharmaceuticals Manufacturing industry will increase at an average annualized rate of 3.0% to $399.7 million. Positive changes in downstream demand for the industry's pharmaceuticals will primarily drive revenue growth. Furthermore, a rise in disposable income and participation in equestrian sports will play a key role in stimulating demand. IBISWorld estimates that per capita disposable income will grow 1.5% annually in the five years to 2016, compared with annualized growth of 0.2% over the past five years. For this reason, industry research firm IBISWorld has added a report on the Equine Pharmaceuticals Manufacturing industry to its growing Animal Health report collection.
In the five years to 2011, IBISWorld estimates that revenue for the Equine Pharmaceuticals industry has decreased at an average annualized rate of 3.3% to $345.3 million. Operators have suffered from a decline in horse and other equine production. A fall in per capita disposable income has constrained horse sales in the consumer market, which is the industry's largest market. This constraint has hampered demand for equine pharmaceuticals, which include vaccinations, antibiotics and parasite control. Furthermore, attendance at horse races has fallen drastically, and some horse tracks have closed down altogether. This factor has minimized the demand for some of the industry's high-margin products, including joint injections. Luckily for industry operators, an increase in horse and other equine production is expected in 2011, contributing to revenue growth of 2.8% during the year.
In the five years to 2011, IBISWorld estimates that the number of firms operating in this industry has declined. Like many pharmaceutical industries, the Equine Pharmaceuticals industry has experienced some consolidation in the past five years. The industry's largest players are large pharmaceutical manufacturers that also produce non-veterinary products, including Bayer AG, Merck and Co. Inc., Pfizer Inc. and Sanofi-Aventis U.S. LLC Many of these companies have sought merger and acquisition opportunities to access intellectual property or increase market share. For example, in 2009, Pfizer acquired Wyeth, and Merck & Co. acquired Schering-Plough.
According to IBISWorld analyst, Caitlin Moldvay, in the five years to 2016, IBISWorld estimates that industry revenue will increase at an average annualized rate of 3.0% to $399.7 million. “A rise in disposable income and participation in equestrian sports will likely boost demand for equine pharmaceuticals,” says Moldvay. Furthermore, rising disposable incomes will increase the likelihood of greater attendance and participation in horseracing during the next five years. While prices of some pharmaceuticals are expected to decline, profit margins are not expected to fall drastically due to continued consolidation among industry operators.
For more information, including latest health trends, statistics, analysis and market share information on Equine Pharmaceuticals, download the full report from IBISWorld on the Equine Pharmaceuticals industry
IBISWorld Industry Market Research Reports Contain:
About this Industry
Industry at a Glance
Key External Drivers
Industry Life Cycle
Products & Markets
Products & Services
Globalisation & Trade
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
Jargon & Glossary
Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189
About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.